Failed Amendment to Federal Budget Bill Could Have Required All Providers to Pass 340B Savings on Insulin to Patients

Sen. Larry Cramer's (R-N.D.) amendment apparently might have required all covered entities, not just health centers, to pass along 340B savings to patients on insulin, injectable epinephrine, or other products. | Source: C-SPAN

A second Republican 340B-related amendment, regarding what covered entities could charge patients for insulin, was offered and then tabled in the U.S. Senate late last week to a budget bill linked to Democrats’ forthcoming COVID-19 relief package.

Sen. Kevin Cramer’s

Read More »

Calif. Health Centers Ask Newsom to Delay Medi-Cal Drug Benefit Shift Until 2022

California health centers have asked Gov. Gavin Newsom to delay the transfer of Medicaid managed care drug benefits to Medicaid fee for service until next year.

California health centers asked Gov. Gavin Newsom (D) on Friday to delay implementing his controversial transfer of Medicaid drug benefits from managed care to fee for service until January 2022, to let health centers “focus on the needs of their

Read More »

Generic Drug Manufacturer Hikma Providing Credits for 340B Overcharges

Hikma Pharmaceuticals USA, the U.S. division of U.K.-based generic drug manufacturer Hikma Pharmaceuticals plc, is crediting 340B covered entities for overcharges on a long list of NDCs from the fourth quarter of 2017 through the fourth quarter of 2020.

The

Read More »

Surprise Amendment to Senate Budget Bill Could Portend Busy 340B Legislative Session

Sen. Mike Braun's (R-Ind.) 340B amendment to require more data reporting echoes the thrust of a bill he introduced in the last session of Congress. | Source: C-SPAN

A Republican amendment offered, then tabled, in the U.S. Senate Feb. 4-5 to a budget bill linked to Democrats’ forthcoming COVID-19 relief package could have led to Senate action related to “improving transparency” in the 340B program “through data reporting.”

Read More »

EXCLUSIVE: Bipartisan U.S. House Group Circulating 340B Sign-on Letter to Becerra

The bipartisan group of six U.S. House members that got 217 total representatives last fall—173 Democrats and 44 Republicans—to sign a letter opposing efforts to replace up-front 340B drug discounts with back-end rebates began circulating a new 340B sign-on letter

Read More »

Drug Companies Are Looking at Multiple Ways to Reduce their 340B Exposure

Drug manufacturer tactics to get a handle on 340B sales growth fall into three buckets: Strategic/legal approaches, claims-scrubbing and other operational capabilities, and “demand-side” ways to reduce exposure to 340B discounts. | Source: IQVIA

Some drug manufacturers have grabbed headlines and precipitated lawsuits for ending 340B pricing on drugs dispensed by contract pharmacies. But behind the scenes, drug companies also are investing in other ways to reduce their exposure to 340B program sales, which

Read More »

Democrats Shake Up Lineup on Key Health Committees Impacting 340B

Sen. Elizabeth Warren (D-Mass.) gave up her seat on the HELP Committee for one on the coveted Finance Committee. | Source: C-SPAN

U.S. Senate Democrats late Tuesday afternoon announced their committee assignments for the 117th Congress. Senate Republicans had not yet announced their committee members as of this morning. However, Sen. Richard Burr (N.C.) will be the ranking Republican on the Health,

Read More »

Two New Manufacturer Notices to 340B Entities on HRSA Website

The generic drug manufacturer recently required to repay covered entities for charging above the ceiling price following an audit has posted a notice on the U.S. Health Services and Resources Administration (HRSA) website about recalculation of ceiling prices and “potential

Read More »

Court Freezes Trump’s Rule Banning Pharma Rebates to PBMs

The Biden administration and Pharmaceutical Care Management Association (PCMA), the trade association for pharmaceutical benefit managers (PBMs), have agreed to postpone, from January 1, 2022, to January 1, 2023, the effective date of the Trump administration rule eliminating safe harbor

Read More »

Sanofi Lifts 340B Contract Pharmacy Requirements for Some Providers But Many Are Still Affected

Health centers and four types of hospitals still have to upload their 340B contract pharmacy claims data to a Sanofi vendor to keep getting 340B discounts on Sanofi products. | Source: Shutterstock

Drug manufacturer Sanofi has exempted 11 of the 16 types of health care providers eligible to participate in the 340B program from its conditions on 340B pricing for its products dispensed by contract pharmacies. However, consolidated health center programs (CH),

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live